NCT02518373已完成2 期
An Open-label Volunteer Study of the Effect of G17DT on the Elevation of Plasma Gastrin Levels After Therapy With a Proton Pump Inhibitor (Omeperazole) in Patients With Treated Stage II/III Colorectal Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 22
- 主要终点
- Change in plasma gastrin level.
研究概览
简要总结
This Phase 2 study was an open label, single-center 18-week study to compare basal and meal stimulated plasma gastrin levels before and after treatment with 3 intramuscular injections of 250 µg G17DT, with and without the concomitant administration of Omeprazole.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects aged 18 to 70 years, inclusive
- •Written informed consent was provided
- •Histologically confirmed Stage II/III colorectal cancer after radical surgery
- •A minimum of 3 months elapsed since completion of the chemotherapy for subjects who had received adjuvant chemotherapy
- •Subject had recovered from any toxic effects of chemotherapy
排除标准
- •Had a known local recurrence of colorectal cancer or presence of metastatic colorectal cancer lesions
- •Was using an inadequate method of contraception (determined at the discretion of the investigator), only for women of childbearing potential who were sexually active
- •Was unable to comply with the protocol
- •Was unable to abstain from H2 receptor antagonists, PPIs or anticholinergics medications for 2 weeks
- •Required H. pylori eradication therapy during the study
- •Had prior vaccination with G17DT or any other product with a similar mechanism of action
- •Had a history of gastric or vagus nerve surgery
- •Had any clinically significant laboratory abnormalities and medical conditions which were unexplained, or, in the opinion of the investigator, did not allow for safe entry of the subject into the study
- •Had contraindications to intramuscular injections (e.g., bleeding disorders or treatment with anticoagulants [except for aspirin])
- •Had serious and unstable cardiovascular or respiratory disease, other malignancy or any other condition that would have jeopardized subject safety or confounded the results
- •Had a known hypersensitivity to diphtheria toxoid, G17DT, any of its components or any similar compound
- •Had any other condition that might have influenced the plasma gastrin level (e.g., achlorhydria, Zollinger-Ellison syndrome)
- •Had used of an investigational drug within the previous month
- •Had taken treatments that alter the immune response such as radiotherapy, corticosteroids, and antineoplastic drugs (Inhaled corticosteroids were permitted.)
- •Had conditions that impaired the immune response (e.g., acquired immune deficiency syndrome)
- •Had a history of drug or alcohol abuse within the past year
- •Was unable to accept a standard breakfast for dietary reasons
研究组 & 干预措施
G17DT & Omeprazole
Experimental
- A 14-day washout period
- An Omeprazole Treatment Period 1 (Day -15 to Day -1)
- A G17DT treatment period (Day 0 to Day 85)
- An Omeprazole Treatment Period 2 (Day 86 to Day 100)
干预措施: G17DT (Biological)
G17DT & Omeprazole
Experimental
- A 14-day washout period
- An Omeprazole Treatment Period 1 (Day -15 to Day -1)
- A G17DT treatment period (Day 0 to Day 85)
- An Omeprazole Treatment Period 2 (Day 86 to Day 100)
干预措施: Omeprazole (Drug)
结局指标
主要结局
Change in plasma gastrin level.
时间窗: up to Day 100
Compare basal and meal stimulated plasma gastrin levels before and after treatment with three intramuscular injections of 250 µg G17DT, with and without the concomitant administration of Omeprazole.
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
1 期
Effect of Blinatumomab in adult patients up to 55 years with acute lymphoblastic leukemiaEUCTR2016-004877-42-ESFUNDACIÓN PETHEMA38
已完成
1 期
Food Effect Study of AG120 in Healthy SubjectsHealthyNCT02579707Agios Pharmaceuticals, Inc.36
已完成
2 期
A phase IIb, open-label study to assess the efficacy, safety, pharmacodynamics and pharmacokinetics of multiple subcutaneous doses of BMN 045 (previously known as PRO045) in subjects with Duchenne muscular dystrophyDuchenne's disease1002830210029317Duchenne muscular dystrophyNL-OMON43779BioMarin Parmaceutical Inc.5
进行中（未招募）
1 期
A study to test if multiple injections of PRO045 are safe and effective in people who suffer from Duchenne muscular dystrophyDuchenne muscular dystrophy resulting from a mutation correctable by PRO045-induced DMD exon 45 skippingMedDRA version: 18.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-005040-10-FRProsensa Therapeutics BV45
进行中（未招募）
1 期
A study to test if multiple injections of PRO045 under the skin are safe and effective in people who suffer from Duchenne muscular dystrophyDuchenne muscular dystrophy resulting from a mutation correctable by PRO045-induced DMD exon 45 skippingMedDRA version: 18.1Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-005040-10-BEBioMarin Nederland B.V.45